235 related articles for article (PubMed ID: 23725999)
1. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Chinnaiyan P; Won M; Wen PY; Rojiani AM; Wendland M; Dipetrillo TA; Corn BW; Mehta MP
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):880-4. PubMed ID: 23725999
[TBL] [Abstract][Full Text] [Related]
2. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Sarkaria JN; Galanis E; Wu W; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Buckner JC
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):468-75. PubMed ID: 20864273
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Mason WP; Macneil M; Kavan P; Easaw J; Macdonald D; Thiessen B; Urva S; Lwin Z; McIntosh L; Eisenhauer E
Invest New Drugs; 2012 Dec; 30(6):2344-51. PubMed ID: 22160854
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
5. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
[TBL] [Abstract][Full Text] [Related]
6. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Butowski N; Chang SM; Lamborn KR; Polley MY; Parvataneni R; Hristova-Kazmierski M; Musib L; Nicol SJ; Thornton DE; Prados MD
Neuro Oncol; 2010 Jun; 12(6):608-13. PubMed ID: 20156802
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
10. Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Massaccesi M; Ferro M; Cilla S; Balducci M; Deodato F; Macchia G; Valentini V; Morganti AG
Int J Clin Oncol; 2013 Oct; 18(5):784-91. PubMed ID: 22892797
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
[TBL] [Abstract][Full Text] [Related]
13. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Drappatz J; Norden AD; Wong ET; Doherty LM; Lafrankie DC; Ciampa A; Kesari S; Sceppa C; Gerard M; Phan P; Schiff D; Batchelor TT; Ligon KL; Young G; Muzikansky A; Weiss SE; Wen PY
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):85-90. PubMed ID: 20137866
[TBL] [Abstract][Full Text] [Related]
16. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
[TBL] [Abstract][Full Text] [Related]
17. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Chinnaiyan P; Won M; Wen PY; Rojiani AM; Werner-Wasik M; Shih HA; Ashby LS; Michael Yu HH; Stieber VW; Malone SC; Fiveash JB; Mohile NA; Ahluwalia MS; Wendland MM; Stella PJ; Kee AY; Mehta MP
Neuro Oncol; 2018 Apr; 20(5):666-673. PubMed ID: 29126203
[TBL] [Abstract][Full Text] [Related]
19. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
